Tag Archives: Ram Selvaraju

Analysts Offer Insights on Healthcare Companies: Inovio Pharmaceuticals (NASDAQ: INO) and EDAP TMS (NASDAQ: EDAP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inovio Pharmaceuticals (INO – Research Report) and EDAP TMS (EDAP – Research Report) with bullish sentiments. Inovio Pharmaceuticals (INO) H.C. Wainwright analyst

Protalix Biotherapeutics (PLX) Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Protalix Biotherapeutics (PLX – Research Report), with a price target of $3. The company’s shares closed on Friday at $0.50. Selvaraju observed: “We note that

Eton Pharmaceuticals Inc (ETON) Initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju initiated coverage with a Buy rating on Eton Pharmaceuticals Inc (ETON – Research Report) today and set a price target of $15. The company’s shares closed on Friday at $8.14. Selvaraju commented: “We have valued

Axsome Therapeutics Inc (AXSM) Received its Third Buy in a Row

After SunTrust Robinson and Cantor Fitzgerald gave Axsome Therapeutics Inc (NASDAQ: AXSM) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics Inc today and

Y-Mabs Therapeutics Inc (YMAB) Receives a Buy from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Y-Mabs Therapeutics Inc (YMAB – Research Report), with a price target of $40. The company’s shares closed on Friday at $21.60. Selvaraju said: “We have

Arcadia Biosciences (RKDA) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Arcadia Biosciences (RKDA – Research Report) today and set a price target of $14. The company’s shares closed yesterday at $4.91. Selvaraju observed: “Valuation methodology, risks and uncertainties. Our valuation